AbbVie Inc. Stock
AbbVie Inc. Stock
AbbVie (ABBV) is a multinational biopharmaceutical company based in North Chicago, Illinois. It was spun off as a separate entity from Abbott Laboratories in 2013 and is primarily focused on the development and commercialization of drugs for the treatment of conditions such as immunology, oncology, and neuroscience. Its key product is Humira, which is used to treat a range of autoimmune diseases, generating a significant portion of the company's revenue. The company also has a pipeline of promising products in various stages of development, making it a reputable player in the pharmaceutical industry.
Pros and Cons of AbbVie Inc. in the next few years
Pros
Cons
Performance of AbbVie Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| AbbVie Inc. | 0.430% | 1.972% | -4.119% | 10.269% | -5.193% | 38.336% | 119.317% |
| Johnson & Johnson | 0.690% | 0.193% | 6.910% | 27.952% | 5.568% | 20.545% | 34.540% |
| Biogen Inc. | -0.210% | 2.587% | -2.394% | 2.044% | -3.403% | -45.817% | -33.964% |
| Pfizer Inc. | 1.100% | 1.125% | 4.311% | -14.102% | 3.477% | -45.360% | -26.490% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Analyzing the financials of AbbVie (ABBV) reveals a company that exhibits both promising strengths and notable challenges. The pharmaceutical giant has managed to sustain significant revenue levels and maintain a relatively solid position within the industry. However, certain metrics highlight potential concerns regarding profitability and debt that merit careful consideration.
Robust Revenue Generation: AbbVie reported total revenue reaching approximately $54.99 billion over the last twelve months (TTM). This impressive figure underscores the company's ability to generate consistent sales, primarily driven by its product portfolio, notably immunology and oncology drugs.
Substantial EBITDA Margin: The EBITDA stands at around $26.25 billion, indicating a solid operational performance in generating earnings before interest, taxes, depreciation, and amortization. With an EBITDA margin of about 47.7%, AbbVie showcases its competent operational efficiency, allowing it to retain a significant portion of its revenue as earnings.
Comments
News
2 High-Yielding Dividend Stocks That Retirees Can Rely on for Recurring Income
If you're a retiree, you may be concerned about how safe it is to invest in the stock market right now. Valuations are high, economic conditions are questionable, and it's getting more difficult to
The Best Healthcare Stocks to Buy With $5,000 in 2026 and Hold Forever
Healthcare-focused investors may be disappointed to learn that the sector underperformed the broader market last year. However, they might also appreciate the fact that there are plenty of stocks in
Could Buying This Stock Today Pay Off Big Over the Next 5 Years?
AbbVie (NYSE: ABBV) has delivered excellent returns over the past decade. It experienced a slight slowdown in recent years as it navigated the loss of patent exclusivity for its former best-selling